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~ Major Isehemic Events After Successful Treatment 
of Sephenous Vein Graft Les ions - -  Importance of 
Anglographicelly "Non-Signiflcent" LeMons 
Stephen G. Ellis, Sorin Brsner, Patrick L. Whitlow. The Cleveland Clinic 
Foundation, Cleveland, OH 
Patients (pts) with pemutaneous intervention (PTCR) of saphenous vein graft 
(SVG) lesions have a high rate of recurrent ischemic events (RIE) (death, 
MI, CABG, PTCR). To Investigate the etiology and timing of these adverse 
outcomes, all pts with suecassfal SVG PTCR in a study with required follow- 
up cath during 1990-93 were studied (n = 102). The initial PTCR in these pts 
was stent = 59 sites, angiaplasty =59, TEC = 45, other = 16. SVG were each 
prospectively divided into 7 segments (seg) (total evaluated = 1067). SVG 
and native (NAT) vessels were separated into those with and without initial 
treatment (rx). 
% of Recurrent Ischemic Events Dudng Interval 
Tim EveN-free Survival SVG-rx SVG-no rx NAT-RX NAT-no rx 
6 moe 67,0% 55 27 4 14 
12 mos 49.0% 57 24 5 14 
18 mos 40.4% 25 50 0 25 
36 mos 25.8% 33 44 0 22 
overall -- 50 30 4 16 
RIE in initially rx'd SVG-seg were correlated with initial % caliper stenosis 
(initial > 75=/0: 43% RIE, 50-75%: 27%, < 50%: 18%, p = 0.01), but not final 
% stenosis. RIE in initially non-rx'd SVG-seg were correlated with reference 
SVG diameter (p = 0.002) and especially with initial % stenosis (initial <_ 30"/0: 
1.8%RIE, 31-40%: 28.6%, 41--50%: 37.8%; p < 0.001). 
Conclusions: 1) RIE after SVG PTCR are common; 2) events from the 
initially treated site(s) predominate for the first 6-12 mos, while events from 
non-treated SVG sites predominate later; 3) the high rate of RIE from non- 
treated ~- 38-50% stenoses suggests a need for increased surveillance in 
pts with these lesions; and 4) the low rate of RIE from treated < 5(P/o stenoses 
suggests that the hypothesis that these "non-significant" lesions might best 
be treated initially should be examined. 
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~76~]  Favorable Results of Followed Debulking by 
Immediate Adjunct Stent Therapy for High Risk 
Saphenous Vein Graft Lesions 
Mun K. Hong, S. Chiu Wang, Jeffrey J. Popma, Lowell F. Satier, Kenneth 
M. Kent, Augusto D, P/chard, Gary S. Minfz, Theresa Bucher, Alan 
J. Merdtt, J. Hope Pacera, Martin B. Leon. Washington Hospital Center, 
Washington, DC 
Stants are the preferred therapy for saphenous vein graft lesions (SVG), but 
appropriate timing (immediate vs. staged) and optimal adjunct therapy before 
stenting in high nsk (totally occluded, thrombus-containieg, or di=genecated) 
SVG are unknown. To determine the safo~, and efficacy of a sbatagy com- 
prising initial thmmbus/tissue debulking followed by immediate stenting, we 
reviewed our expenences with transluminal extraction atherectomy (TEC, n 
= 36) and excimer laser angioplasty (ELCA using 3alice flush technique and 
2 mm catheters, n = 81) before stanting in high nsk SVG. Baseline charac- 
tedsflcs were similar for TEC + Stent vs ELCA + Stent and for the overall 
high dsk SVG group (n = 117) included 92% unstable angina, mean graft age 
of 8.7 yrs, 21% thrombus, 9% total occlusions, and 20°/,, SVG degeneration, 
Procedure success was defined as final diameter stsnosis < 50"/,, without 
major complications (death, Q-wave MI, or emergency CABG). Non-Q wave 
MI was defined as CPK-MB > 5 x normal. 
TEC + slant ELCA + slent 
Procedural success (%) 100 100 
Major ischemic omplications (O/o) 0 0 
Non-Q Wave MI (%) 15.6 8.7 
In-lab closure (%) 2.9 0 
No-reflow (%) 2.2 0 
We conclude: Dabulking with TEC or ELCA followed by immediate stent- 
ing results in excellent procedure success and rare ischemio r angiographic 
complications. Thus, TEC or ELCA + stents may be the prefen'ed interven- 
tional therapy for high dsk SVG lesions. 
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~ Anatomy Reconstruction of Native Coronary 
Armnes and Veto Grafts With the Less Shortening 
Serf-Expandable Wallstent 
Jean Marco, Jean Fajadet, Philippe BnJcel, Christian Jordan, 
Bernard Cass~gneau, Jean-Piewe Laurent. Clinique Pasteur, Toulouse, 
France 
The modifications in braiding angle of the self-expanding Wallstent has re- 
suited in less shortening upon expansion and a reduction in radial force. 
The customized range of diameters (3.5--6.0 ram) and lengths (18-49 ram) 
after the deployment of an oversized Walls'tent allow to treat very long and 
complex lesions in native coronary artefias or grafts. 
Between December 1994 and July 1995, 60 patients(10ts ) with complex 
long (lesion length: 29.8:1:14.9 mm) were treated with implantation of 1 
(3910ts) or more (21 10is) Walistants elected wilh an unconstrained nominal 
diameter of 1.5 mm greater than maximal diameter vessel (MDV). Post stent 
delivery, high pressure (> 15 arm) intra stent inflation was systamaticaly 
performed, 
The vessel disthl~lion was RCA: 20, LAD :15, LCX :9, SVG :21 The 
average nominal diameter and length of deployed Wallstent was 4.6 4- 0.64 
mm and 33.3 a- 9.2 ram. The pre-MVD was 3.48 ± 0.42 mm and the post 
stant minimun lumen diameter was 3.4 4- 0.51 ram. Post procedure therapy 
consisted of aspidn and ticlupidine. One patient (1.7%) stopped ticlopidine on 
day 10 and sustained subacute closure on day 17 successfully treated with 
streptokinase. No other subecute thmmbeses, deaths, myocardial infarctions 
or repeat infervenfions occurred between 1 to 7 months of clinical follow-up. 
Conclusion: The use of oversized and long Wallstent allows a reconstrution 
of lumen and a resetting of the vessel size. Initial clinical results with ticlopidin 
+ aspidn appear promising. Long term angiographic follow-up remains to be 
determined. 
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VT"~'~ Compaseionate Endoluminal Grafting for  
Peroutsneous Treatment of Aortocoronary SVG 
Disease 
R.R. Heuser, G.T. Reynolds, C. Papazoglou, E.B. Diethrich, R. Mukherjee. 
Arizona Heart Institute, Phoenix, AZ 
Endoluminal grafts (ELG) composed of an expandable PTFE ~,,be graft/Palmaz 
slant device were implanted percutaneousty with a low-profile ~.ystem to treat 
saphenous vein graft (SVG) disease in 6 patients with no Other :~urgical or 
percutaneous treatment options. Mean patient age was 64 y (range 47-77). 
Three patients had aneurysms, 2 had multiple restenoses, and 1 had diffuse 
disease. Two cases were unsuccessful as a msuft of prolonged hypotaasion 
dudng attempted graft insenfon in one case, which responded to fluid and 
blood adminislratien, and the inability to predilate the lesion in the second 
case. Procedural success was achieved in four patients (67%). In these 
cases, ELGs were deployed in the SVG to the right coronary artery in one 
patient and in the SVG to the obtuse marginal branch in three patients. Mean 
graft age was 122 months (range 19-240). Mean lesion length was 38 mm 
(range 25-49) and graft length was 68 mm {range 52-92). At mean 260<1 
follow-up (range 186-392), angiography confirmed widely patent grafts in 
two patients and three instances of subasute thrombosis in the remaining 
two patients. At last follow-up, all 4 patients remained free of angina. These 
early results indicate that ELGs may be an effective trealment for aneurysmal 
and severely diseased SvGs in pa~ents with poor percutanaous or surgical 
options. The size of the diseased SVG may play a role in the success of the 
procedure: in this sades, subacute thrombosis has been seen only in smaller 
grafts (< 3 ram); grafts > 4 mm had no aegiographic, angioscopic, or ultra- 
sound evidence of intimal growth. Further study is warranted to determine if
the nonporous PTFE graft is resistant to intimal growth in follow-up. 
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Autologous Vein Graft-Coated Stent for  the 
Treatment of Coronary Artery Disease: Immediate 
Results After Peroutaneous Implantation in Humans 
Chdsledoulos Stofanadis, Elefthedus Tslamis, Konstantinos Toutouzas, 
Charalambos Vlachopouloe, ioannis KalSkazeros, Costas Stmtos, 
Manolis Vevuranalds, Asimakis Sidefis, Pavio~, Toutouzas. Athens 
University, Greece 
Background: Acute closure and late restenosis remain the major limitations 
of stenting. We have earlier eported the successful experimental pplication 
of the autalog0us vein graft-coated stent (AVGCS), that consists of a con- 
ventional stent covered by a vein graft. We now report he immediate results 
of the implantation of the AVGCS in 13 patients (pts) with coronary artery 
disease. Methods: The right cephalic vein was isolated and approximately 
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a 3 cm graft was removed and cleared from the boundaw tissue, so that 
it became sulfidentty thin. A Palmaz or a Palmaz-Schatz slant was then 
covered by the vein graft. Thirteen AVGCSs were implanted percutaneously 
through a 10F guiding catheter in 13 pts suffering from angina (12 male, 1 
female, mean age 58 4- g years). Two AVGCSs were tcwplanted in by-pass 
vein grafts, 2 in the left anterior descending artery, 8 tn the right coronary 
adery, and one in the left elmumflex. Quantitative coronary angiography was 
performed to measure the minimal uminal diameter (MLD). The pts were 
discharged from the hospital under anticoagulaticn treatment. Results: De- 
ployment of the AVGCS was successful in all caseS, The mean MLD was 
incraesad from 0.41 :E 0.t to 3.2f ± 0.2 mm (p < 0.001). No complications 
were encountered uring the procedure. The TST was negative in all 4 pts, 
that underwent he examination. All I~tS were free of angina at a follow-up 
period of 4.2 :E 1.5 monthS. Conclusion: Implantation of AVGCS in humans 
is a feasible procedure with excellent immediate results. Further studies 
am warranted, however, to investigate the efficacy of AVGCS, in terms of 
reducing the incidence of acute thrombosis and late mstenosia. 
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~ Prognostic Value of  History of  Congestive Heart a 
Failure in Patients Undergoing Pereutaneous 
Coronary Interventions 
R. David Anderson, Nancy M. Wildermann, David R. Holmes Jr., 
Christopher M, O'Conner, Robert A. Harrington, Hany R, PhillipS, Robert 
M. Califf, E. Magnus Ohman. Duke University, Durham, NC 
To evaluate the clinical and engiogrephiC outcomes in pts with LV dysfunction 
undergoing PTCA/DCA with and without symptoms of CHF we examined 
2017 pts. Pts were pooled from 4 muiticenter tdals with 6 to 9 me follow-up 
and grouped according to EF: < 30%, 30-40%, and > 40%. Pts with reduced 
EF were morn frequently male (89°/= vs 77% vs 73%), had more CHF (48% 
vs 17% vs 9%), previous CABG (48% vs 27% vs 15%), MI (79% vs 83% vs 
51%) and 3-vessel disease (13% vs 11% vs 6%). Pts with EF < 30% had 
lower procedural success (QCA stenosia _< 50%) rates (61% vs 81% vs 81%) 
but similar restenosfs rates HIP/o vs 47% vs 47%). Mortality and composite 
outcome (death, MI, CABG and repeat PTCA) were: 
EF < 30% EF 30-40% EF > 40% 
-CHF 'H3HF -CHF +CHF -CHF +CHF 
n -24  n=S2 n=153 n=31 n= 1671 n=gg 
Death (30 d) 8% 14% 1% 3% 1% 2% 
Death (e me) 17% 32% 3°4, 6% 1% 4% 
Comp (9 me) 46% 64% 34% 39% 37% 28% 
Muitivariable logistic regression showed no association between EF/CHF 
and 9 me rates of MI, CABG or PTCA. A significant association between 
mortality and EF (x 2 = 23, p = 0.0001) and history of CHF (x 2 = 24, p = 
0.006) was obsewed. A clinical history of CHF added to EF (p = 0.02) in 
predicting 9 me mortality. In conclusion, CHF history and EF am important 
clinical variables that portend poor eady and late outcomes in pts undergoing 
percuteneous interventions. 
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~ Intravaecular Ultrasound Evidence for  Balloon 
Oversizlng in Diabetics: A Factor in Higher 
Complication Rates? 
Anthony C. De France, E. Murat Tuzcu, Kheled M. Zinda, William 
A, Magyar, Nirav Shah, David J. Molitemo, Patrick L. Whitlow, Irving France, 
Stephen G. Ellis, Steven E. Nissen. Cleveland Clinic, OH 
Objectives: Diabetic paflents have higher beiton angioplasCy complication 
rates and increased risk of mstenosis. We sought to determine whether 
dilfersnces in vessel size or morphology by intravasculer ultrasound could 
explain this phenomenon. 
Methods: We evaluated 313 interventions in244 patients who underwent 
primary or adjunctive balloon angiopiasty. Angiographie and ultrasound lumi- 
nal diameters, media-edvenUUa diameter and area, and degrees of arc with 
calcification were measured at "normal" reference sites adjacent to target 
lesions. Measurements were pedorrned in a laboratory blinded to clinical 
variables. Patients with a history' of diabetes were compared to patients 
without known diabetes 
Recurs: Relerence Sttes Diabetes No Diabetes jo 
n = 46 n = 267 value 
Angto Lumen Diameter (ram) 3.36 3,35 NS 
Ultrasour~ Lumen Diameter tram) 3,15 3.21 NS 
Maximum Balloon Size (ram) 3A3 3.47 NS 
Extent of Cs~t ion  (degrees) 33.6 19.t 0.0005 
Media-Adventltls Area (ram 2) 12.77 14.07 0.02 
Salloon/Aegio Diameter Ralio 1,02 1.04 NS 
Bagoon/IVUS Media Ratio 0.86 0.82 0.03 
Conc/asior~: Thus, diabetic and non-diabetic patients have compara~e 
engiagraphtc and ultrasound mr..fence vessel diameters, are dilated with 
similar balloon sizes, and have cempamble ratios of balloon size to anglo- 
graphic reference diameter, Hnwever, diabetics have much higher likelihood 
of ultrasound-detected calcification and have a significantly smaller media- 
adventttia area by ultrasound, This phenomenon results in a significantly 
higher balloon to media ratio which may explain the higher complication 
rates in clinical studies, 
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~ Immediate and Long-Term Clinical Outcome in 
Patients Undergoing Angioplasty of Occluded Vein 
Grafts 
Peter B. Berger, Malcolm R. Bell, Robert Simari, Guy S. Reeder, Diane 
E. Grill, David R. Holmes Jr.. Mayo C/In/c, Rochester, MN 
To determine the immediate and long-term clinical outcome associated with 
PTCA of occluded vein grafts, we analyzed 77 consecutive patients (LotS) 
without an MI 3 24 hours in whom PTCA of an occluded vein graft was 
attempted. New devices (slants, atherectomy, or laser) were used in 48=/° of 
procedures; intravascuiar thmmbolytic therapy was used in 23%. Myocardial 
infarcticn (MI) had occurred 1 to 7 days pdor to PTCA in 22 pts (29%). Mean 
age was 65 yrs: 8"P/O were male. Class 3 or 4 angina was present in 85=/o; 
79% had a prior MI, 26% had a hx of CHR Mean graft age was 7.5 =k 3.9 
yrs. Angiographic success (< 50% residual stenosis) was achieved in 71% 
of procedures (in 68=/= of pts with a recent MI vs 73% in the remaining lOtS). 
The 30 day mortality was 5.2%; 1% of pts suffered a Q wave MI and 8% 
underwent repeat CABG within 30 days. Univariate analysis indicated that 
the graft age, but not angiographio failure, was associated with death and MI 
throughout he hospitalization and foflow-up period. During follow-up (mean 
2.0 ~: 1.9 yrs), them was no difference in 3 yr survival between pts in whom 
angiographtc success had and had not been achieved (68% vs 76%), nor 
was them a difference in freedom from either MI (75% vs 74%), repeat PTCA 
or CABG (49% vs 48%) orthe development of severe angina (36% vs 42=/o). 
We conclude that PTCA of occluded vein grafts is successful in only 71% of 
cases, event rates am high in the subsequent 30 days, and when successful, 
adveme events dudng the following 3 year~ am no less frequent han in pts 
in whom PTCA was unsuccessful. Randomized trials comparing PTCA to 
repeat CABG and medical therapy in such pts am needed. 
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~ Clinical Outcome of  "High-Risk" vs  "Elective" 
Patients Undergoing Percutaneous Coronary 
Intervention: Results f rom IMPACTdl 
James J. Fergusen, Timothy J. McDonough, Seth J. Wodey, William 
J. French, John C. CorbeUi, James C, Blankenship, Daniel Carey, Frank 
V. Aguirre, Robert A, Harrington, J David Talley, A. Michael Lincetf, William 
C. Sheldon, Bonnie H. Weiner, Jan R. Resar, James E. Tcheng, Eric 
J. Topoi, Robert M. Califf on behalf of the IMPACT-II Investigators, Texas 
Heart Institute, Houston, TX 
IMPACT-II was a randomized, plecabo-controfled trial of two doses of the 
GP lib/ilia blocker, lntegmlin, in 4010 patients undergoing PTCA, with pa- 
tients stratified at enrollment to either a"high-risk" (unstable angina with EKG 
changes or acute MI) or"elective" ann. Paradoxically, Integmlin appeared to 
reduce adverse outcome events (30~ay combined rate of death, MI, or ur- 
gent revascutatizaticn) inelective but not high-risk patients. Moreover, event 
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